Attenuated strains of vibrio cholerae and lyophilised vaccines containing same

• Main Authors: AVICENCIO CARIDAD,FANDO CALZADA RAFAEL ALFREDO, CAMPOS GOMEZ JAVIER,MOREIRA HERNANDEZ TOMAS MARCEL,RODRIGUEZ GONZALEZ BORIS LUIS,MARRERO DOMINGUEZ KAREN,MARTINEZ GUTIERREZ ERIEL,LEDON PEREZ TALENA YAMILE,SILVA LARRANAGA YUSSUAN,SUZARTE PORTAL EDITH
• Format: Patent
• Language: English
• Published: 31.05.2006
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; TESTING STATIC OR DYNAMIC BALANCE OF MACHINES ORSTRUCTURES; TESTING STRUCTURES OR APPARATUS NOT OTHERWISE PROVIDED FOR; VINEGAR; WINE

The present invention discloses new live attenuated strains for oral immunization against cholera that are provided in freeze dried formulations for long term storage and administration to humans. These strains combine the two most important properties of live attenuated cholera vaccine candidates. One such property is being well tolerated by people ingesting them. This was achieved by virtue of mutations already described in the art. The second property is having enhanced environmental safety due to the absence of VGJ¦ DNA in their genomes and also due to null mutations in the mshA gene or other spontaneous mutations conducive to the lack of MSHA type IV fimbria on the bacterial surface. This was done envisioning that VGJ¦ is a filamentous phage able to recombine with CTX¦ and disseminate the cholera toxin genes. This VGJ¦ phage as well as the VGJ¦-CTX¦ recombinants uses the MSHA fibers as receptor. Being devoid of MSHA fimbria the vaccine candidates are protected from acquiring CTX¦ from the recombinant hybrid VGJ¦-CTX¦. Being devoid of VGJ¦, the vaccine candidates are impaired in the dissemination of CTX¦, via VGJ¦.